Korea Exchange · Healthcare
Hyundai Pharmaceutical stock from India: price, numbers and tax
Hyundai Pharmaceutical (004310) is not currently available to trade on Paasa; this guide covers the price, the numbers and the Indian tax treatment.
By Paasa · Updated
Hyundai Pharmaceutical at a glance
- Price
- ₩7,760.00-₩410.00 (5.02%)
- Market cap
- ₩181.97B
- Day range
- ₩7,720.00 – ₩8,240.00
- P/E
- 47.65
- Dividend yield
- 0.39%
- Volume
- 732.19K
- 1 month
- -20.57%
- 6 months
- -10.08%
- YTD
- -8.92%
- 1 year
- +102.08%
- 5 years
- +40.07%
Hyundai Pharmaceutical statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | ₩191.8B | ₩175.7B | ₩180.8B | ₩162.7B | ₩139.8B |
| Gross profit | ₩78.2B | ₩73.4B | ₩75.2B | ₩68.8B | ₩56.3B |
| Operating income | ₩3.3B | ₩180.9M | ₩6.9B | ₩8.0B | −₩1.6B |
| Net income | ₩2.5B | −₩574.9M | ₩6.1B | −₩164.6M | −₩3.2B |
| Earnings per share | ₩96.28 | −₩22.41 | ₩225.81 | −₩5.92 | −₩113.82 |
| EBITDA | ₩7.6B | ₩3.9B | ₩13.2B | ₩10.0B | ₩671.0M |
| Total assets | ₩166.9B | ₩156.4B | ₩154.6B | ₩181.2B | ₩163.9B |
| Total debt | ₩50.1B | ₩48.1B | ₩39.2B | ₩39.4B | ₩29.8B |
| Cash and short-term investments | ₩2.5B | ₩10.5B | ₩18.6B | ₩34.5B | ₩22.2B |
| Shareholders' equity | ₩82.1B | ₩79.1B | ₩84.7B | ₩86.6B | ₩86.6B |
| Operating cash flow | −₩123.3M | −₩2.4B | −₩4.5B | ₩11.6B | ₩5.1B |
| Free cash flow | −₩4.7B | −₩13.6B | −₩10.6B | ₩5.0B | −₩1.7B |
| Capital expenditure | −₩4.6B | −₩11.2B | −₩6.1B | −₩6.6B | −₩6.8B |
Fiscal years as reported, the latest ending 30 Nov 2025. Figures in KRW; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| KUKJE PHARMA | 002720.KS | ₩4,270.00 | ₩90.35B |
| Enzychem Lifesciences | 183490.KQ | ₩990.00 | ₩83.79B |
| CKD Bio | 063160.KS | ₩14,010.00 | ₩76.86B |
| Ildong | 000230.KS | ₩6,160.00 | ₩71.09B |
| Sugentech | 253840.KQ | ₩4,545.00 | ₩69.49B |
| P&S Robotics | 460940.KQ | ₩5,000.00 | ₩67.28B |
| Yuyu Pharma | 000220.KS | ₩3,840.00 | ₩60.47B |
| Yuyu Pharma | 000225.KS | ₩3,605.00 | ₩56.77B |
Peers as grouped by the data provider. This is not an investment recommendation.
Why invest in Hyundai Pharmaceutical from India
What Hyundai Pharmaceutical does
Headquartered in Seoul, South Korea, Hyundai Pharmaceutical Co., Ltd. is an international manufacturer and distributor of a diverse portfolio that includes pharmaceutical products, health food beverages, and medical equipment. The company's extensive offerings comprise both prescription (ETC) and over-the-counter (OTC) remedies, addressing a broad spectrum of therapeutic areas. Hyundai Pharmaceutical operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
What tax do I pay in India when I sell Hyundai Pharmaceutical shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the KRW/INR rate on the day you bought and the day you sold, so the currency move is part of the gain.